Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
03/2005
03/02/2005EP1509537A2 Cellular accumulation of phosphonate analogs of hiv protease inhibitor compounds and the compounds as such
03/02/2005EP1509532A1 1-thia-3-aza-dibenzoazulenes as inhibitors of tumour necrosis factor production and intermediates for the preparation thereof
03/02/2005EP1509530A1 2-thia-dibenzoazulenes as inhibitors of tumour necrosis factor production and intermediates for the preparation thereof
03/02/2005EP1509529A2 Esters in position 20 of camptothecins
03/02/2005EP1509528A2 1,3-diaza-dibenzoazulenes as inhibitors of tumour necrosis factor production and intermediates for the preparation thereof
03/02/2005EP1509526A2 Imidazo(1,2-a)pyrazin-8-ylamines, method of making, and method of use thereof
03/02/2005EP1509524A1 Xanthine phosphodiesterase v inhibitor polymorphs
03/02/2005EP1509523A2 Triazaspiro compounds useful for treating or preventing pain
03/02/2005EP1509522A1 1-(aminoalkyl)-3-sulfonylazaindoles as 5-hydroxytryptamine-6 ligands
03/02/2005EP1509521A2 1h-imidazo[4,5-c]quinoline derivatives in the treatment of protein kinase dependent diseases
03/02/2005EP1509520A1 Use of benzo(c)quinolizinium derivatives for the treatment of diseases that are linked to smooth muscle cell constriction
03/02/2005EP1509519A1 Crystalline fluoroquinolone arginine salt form
03/02/2005EP1509518A1 Calcium receptor modulating agents
03/02/2005EP1509516A1 Inhibitors of the gpib -vwf interaction, their preparation and use
03/02/2005EP1509515A2 Substituted 4-aryl-4h-pyrrolo 2,3-h chromenes and analogs as activators of caspases and inducers of apoptosis and the use thereof
03/02/2005EP1509514A1 Anthelmintic and insecticidal thiophene derivatives
03/02/2005EP1509511A1 Manufacture of ascorbic acid esters
03/02/2005EP1509509A1 Glucagon antagonists/inverse agonists
03/02/2005EP1509507A2 Mitotic kinesin inhibitors
03/02/2005EP1509506A1 Pyridazine derivatives
03/02/2005EP1509504A1 7-phenylsulfonyl-tetrahydro-3-benzazepine derivatives as antipsychotic agents
03/02/2005EP1509501A1 1-(aminoalkyl)-3-sulfonylindole and -indazole derivatives as 5-hydroxytryptamine-6 ligands
03/02/2005EP1509499A1 Pyrrole compounds for the treatment of prostaglandin mediated diseases
03/02/2005EP1509498A1 Pentafluorosulfanyl-benzoylguanidine, method for the production thereof and its utilization as medicament or diagnostic agent and medicament containing same
03/02/2005EP1509497A1 Calcium receptor modulating arylalkylamines
03/02/2005EP1509495A1 Anilino liver x-receptor modulators
03/02/2005EP1509494A2 Amidoacetonitrile compounds
03/02/2005EP1509492A2 Short-acting sedative hypnotic agents for anesthesia and sedation
03/02/2005EP1509489A1 Amines that inhibit a mammalian anandamide transporter, and methods of use thereof
03/02/2005EP1509285A2 Synergistic composition of trans-tetracos-15-enoic acid and apocynin and use thereof
03/02/2005EP1509268A1 Drug delivery assembly
03/02/2005EP1509251A2 Nucleic acids, polypeptides, and methods for modulating apoptosis
03/02/2005EP1509250A1 Methods compositions and articles of manufacture for modulating bone growth
03/02/2005EP1509249A2 Inclusion complexes of rosiglitazone
03/02/2005EP1509248A1 Combination of angiotensin ii receptor blocker and beta-blocker for secondary prevention of myocardial infarction
03/02/2005EP1509247A1 Use of inhibitors of phospholipase a2 for the treatment, prevention or diagnosis of neural inflammatory or demyelinating dieseases
03/02/2005EP1509236A2 Treatment and prevention of abnormal scar formation in keloids and other cutaneous or internal wounds or lesions
03/02/2005EP1509235A1 Method for the protection of endothelial and epithelial cells during chemotherapy
03/02/2005EP1509234A1 Treatment of mucositis
03/02/2005EP1509233A1 Liquid formulation of decitabine and use of the same
03/02/2005EP1509232A1 A combination of an nmda-antagonist and acetylcholine esterase inhibitors for the treatment of alzheimer's disease
03/02/2005EP1509231A1 Peritoneal dialysis solution with taurolidine
03/02/2005EP1509230A2 Method of treating cancer using kinase inhibitors
03/02/2005EP1509229A1 Compositions comprising hepoxilin analogs and their use in the treatment of cancer
03/02/2005EP1509228A1 Derivatives of 2-(1-benzyl-1h-pyrazolo (3, 4-b)pyridine-3yl) -5-(4-pyridinyl)-4-pyrimidine amine and the use thereof as guanylate cyclase stimulators
03/02/2005EP1509227A1 A buffered, liquid nicotine composition for pulmonary administration
03/02/2005EP1509226A2 Small molecule inhibitors of her2 expression
03/02/2005EP1509225A1 Method for the use of pyranoindole derivatives to treat infection with hepatitis c virus
03/02/2005EP1509224A1 Methods using a combination of a 3-heteroaryl-2-indolinone and a cyclooxygenase-2 inhibitor for the treatment of neoplasia
03/02/2005EP1509223A1 Hepatoprotective activity of 10-o-p-hydroxybenzoyiaucubin
03/02/2005EP1509222A1 Adduct of topiramate and tramadol hydrochloride and uses thereof
03/02/2005EP1509221A1 N-acylaminoacetonitrile derivatives and their use for controlling parasites
03/02/2005EP1509220A1 A pharmaceutical composition for the treatment of seborrhea containing 4-hydroxy-5-methoxy-4- 2-methyl-3(3-methyl-2-butenyl)-2-oxiranyl]-1-oxaspiro 2,5]octan-6-one
03/02/2005EP1509219A1 Methods and compositions for the treatment of graft failure
03/02/2005EP1509218A1 Peptide deformylase inhibitors
03/02/2005EP1509217A1 Monotherapy for the treatment of amyotrophic lateral sclerosis with cyclooxygenase-2 (cox 2) inhibitor(s)
03/02/2005EP1509216A1 Active ingredient salts and esters of 1-dimethylamino-3-(3-methoxy-phenyl)-2-methyl-pentan-3-ol and 3-(3-dimethylamino-1-ethyl-1-hydroxy-2-methyl-propyl)-phenol
03/02/2005EP1509215A1 Method for the inhibition of atrophy or for treatment or prevention of atrophy-related symptoms in women
03/02/2005EP1509213A2 Acetamides and benzamides that are useful in treating sexual dysfunction
03/02/2005EP1509212A1 Novel chromium (iii) alpha amino acid complexes
03/02/2005EP1509210A1 Plaster containing fentanyl
03/02/2005EP1509209A1 Compositions and method for transmucosal drug delivery and cryoprotection
03/02/2005EP1509207A1 Pharmaceutical composition containing oxcarbazepine and having a controlled active substance release
03/02/2005EP1509205A1 Pharmaceutical composition having a delayed active substance release, and method for the preparation thereof
03/02/2005EP1509203A2 Delivery of nucleic acid-like compounds
03/02/2005EP1509202A1 Novel high viscosity embolizing compositions comprising prepolymers
03/02/2005EP1509201A1 Film-shaped preparations with improved chemical stability containing active substances and method for the production thereof
03/02/2005EP1509199A1 Dry powder inhalant composition
03/02/2005EP1509188A2 Compounds active at the glucocorticoid receptor ii
03/02/2005EP1509182A1 Implantable polymeric device for sustained release of buprenorphine
03/02/2005EP1509181A1 Personal care article and method for inhibiting attachment of yeast to skin
03/02/2005EP1509086A2 Htlv-i tax induced killing of p53 null cancer cells
03/02/2005EP1435998A4 Method for treating hepatitis c virus infection in treatment failure patients
03/02/2005EP1416966A4 Methods for treating joint inflammation, pain, and loss of mobility
03/02/2005EP1412353B1 Imidazopyridinones as p38 map kinase inhibitors
03/02/2005EP1384476B1 Azolylcarbynol derivatives of aryl (or heteroaryl) for the treatment of respiratory diseases
03/02/2005EP1345591B1 Pharmaceutical aerosol formulation
03/02/2005EP1296650B1 Methods and compositions for treating pain of the mucous membrane
03/02/2005EP1282084B9 Method for preparing pyrimidone derivatives with antifungal activity
03/02/2005EP1278741B1 Muscarinic agonists
03/02/2005EP1244649B1 Cyclic amp-specific phosphodiesterase inhibitors
03/02/2005EP1241943B1 Use of polysiloxanes containing quaternary amino groups as formulation auxiliary agents, and agents containing the same
03/02/2005EP1201762B1 Process for producing lycopen
03/02/2005EP1194148B1 Type v pde-inhibitors for the treatment of cystic fibrosis
03/02/2005EP1180102B9 Mutual prodrugs of amlodipine and atorvastatin
03/02/2005EP1180018B1 Use of antiseptics in the manufacture of a pharmaceutical preparation for the prevention and treatment of infections and/ or functional tissue remodelling in the interior of the human body
03/02/2005EP1169065B1 Methacoline or histamine formulations for detecting asthma
03/02/2005EP1165563B1 Bicyclic heterocycles, method for producing them and their use as herbicides and pharmaceutical agents
03/02/2005EP1142576B1 Drug compositions for the treatment of ocular hypertension or glaucoma
03/02/2005EP1140240B1 Injectable hyaluronic acid derivative with pharmaceuticals/cells
03/02/2005EP1140017B1 Water-insoluble drug delivery system
03/02/2005EP1129084B1 Thiazole derivatives as ppar gamma ligands
03/02/2005EP1123100B1 Improving memory by the administration of delta 5-androstene-3 beta-ol-7,17-dione and 3 beta esters thereof
03/02/2005EP1115399B1 Use of a pharmaceutical composition containing, in combination, an antagonist of the angiotensin ii at 1? receptors and indomethacin for making a medicine treating chronic glomerulonephritis
03/02/2005EP1109532B1 Oral micro-emulsion composition of silybin
03/02/2005EP1086082B9 Arylsubstituted olefinic amines and their use as cholinergic receptors agonists
03/02/2005EP1077698B1 Metabolites of ecteinascidin 743
03/02/2005EP1070067B1 Cytotoxic alkaloid derivatives including asmarine a and b isolated from a sponge
03/02/2005EP1042279B1 Substituted beta-alanines
03/02/2005EP1034207B1 BIODEGRADABLE LOW MOLECULAR WEIGHT TRIBLOCK POLY(LACTIDE-co-GLYCOLIDE) POLYETHYLENE GLYCOL COPOLYMERS HAVING REVERSE THERMAL GELATION PROPERTIES
1 ... 4769 4770 4771 4772 4773 4774 4775 4776 4777 4778 4779 4780 4781 4782 4783 4784 4785 4786 4787 4788 4789 ... 7860